Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III first-line study of D-0316 versus icotinib in EGFR-mutant advanced non-small cell lung cancer
CTR20192356Phase 3Completed
- Sponsor
- InventisBio
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of befotertinib in non-small cell lung cancer (NSCLC), Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by InventisBio. Started Dec 2019; status: completed.
02
Drugs
befotertinib
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on CTR20192356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192356.